



InvisiMask™ Nasal Spray

Frequently Asked Questions

1. Who is Eureka Therapeutics?




[Eureka Therapeutics, Inc.](#) is a clinical stage biotechnology company developing novel T-cell therapies to treat solid tumors based in Emeryville, California. Our core technology centers around our proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of solid tumors and hematologic malignancies. ET140203, the Company's lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer.

2. What is the InvisiMask nasal spray?

The InvisiMask nasal spray consists of human IgG antibodies directed against the spike protein from SARS-CoV-2, the virus that causes COVID-19. We envision the InvisiMask nasal spray to be used daily to provide an important line of personal protection against SARS-CoV-2 infection. Eureka's antibodies have also been engineered with a proprietary adhesion technology that increases the retention of the antibody on respiratory mucosal surfaces, extending the duration of protection from infection.

3. How does the InvisiMask nasal spray work?

Eureka's InvisiMask human antibody nasal spray was designed to neutralize SARS-CoV-2 from airborne droplets and particles in the nasal cavity, the primary entry point of SARS-CoV-2 infection. The Eureka antibodies function by binding to the S1 spike protein of SARS-CoV-2 and preventing the virus from binding to the ACE2 receptor on cells in the upper respiratory system. This blocks SARS-CoV-2 from entering cells and triggering an infection.

| | |
|---|---|
|  | <p>Step 1:</p> <p>Antibodies administered by InvisiMask™ nasal spray</p> |
|  | <p>Step 2:</p> <p>Antibodies adhere to the upper respiratory tract</p> |
|  | <p>Step 3:</p> <p>Antibodies neutralize the SARS-CoV-2 virus</p> |

4. How long can the InvisiMask nasal spray protect against SARS-CoV-2 infection?

At the lowest dose of 25 µg, the antibodies provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested (10^7 pseudotype virus particles administered intra-nasally).

5. Why should I care about the InvisiMask nasal spray when vaccines and therapeutics are available?

The purpose of the InvisiMask nasal spray is to prevent an infection from occurring in the first place, and it provides an additional tool to slow the spread of COVID-19. While vaccines and therapeutics have many benefits, they also have shortcomings. In the case of vaccines, the recipient's immune system would need to mount an effective immune response upon vaccination to provide protection. This may not be the case for everyone, and not everyone (i.e. people with severe allergies) is suitable to be vaccinated. Moreover, it is still undetermined how long the protection from infection lasts after vaccination with the various SARS-CoV-2 vaccines. Therapeutics, on the other hand, are given to people only after they have become infected by the virus. We envision InvisiMask to provide an additional layer of protection, even after someone has been vaccinated.

6. What is the target market for the InvisiMask nasal spray?

The InvisiMask nasal spray is a complement and not a substitute for vaccines, therapeutics or face masks in slowing the spread of COVID-19. Certain populations could benefit immediately from our nasal spray such as young children, seniors, frontline health workers, the immunocompromised, athletes, people who do not respond well to vaccines, or people in situations in which face mask wearing is impractical.

7. Is the InvisiMask nasal spray commercially available?

No, the InvisiMask nasal spray is not commercially available at this time. It will need to be first tested in clinical trials for safety and efficacy in humans before authorization from the U.S. Food and Drug Administration (FDA) is sought for commercial use.

8. How much will the InvisiMask nasal spray cost?

We envision the InvisiMask nasal spray to cost less than one US Dollar for each daily dosage.

9. Will the InvisiMask nasal spray be available over the counter?

Commercialization of the InvisiMask nasal spray is currently being explored. Availability for over the counter use will depend on FDA approval. In contrast to the current anti-SAR-CoV-2 vaccines that require storage at sub-zero temperatures, the InvisiMask nasal spray can be stored and used at room temperature which would simplify distribution and expand

access. In its current formulation, the InvisiMask nasal spray is stable for at least 2 weeks at 98.6°F (37°C) and is expected to have an even longer shelf life at room temperature.

10. What is the status of your clinical trials for the InvisiMask nasal spray?

Eureka is preparing an Investigational New Drug (IND) application with the FDA to conduct a clinical trial of the InvisiMask nasal spray.

11. Are there any other anti-SAR-Cov-2 antibody drugs that have been approved?

Yes, in November 2020, the FDA granted Eli Lilly (bamlanivimab) and Regeneron (casirivimab and imdevimab) emergency use authorization (EUA) to use their anti-SARS-CoV-2 antibody therapies intravenously in patients with confirmed cases of COVID-19.

12. How and where will InvisiMask nasal spray be manufactured?

The manufacturing and scale-up processes for monoclonal antibodies are well-established. We expect that the InvisiMask nasal spray will be locally manufactured in each of the territories around the world in which it will be sold.

13. Why did Eureka use a human antibody?

Due to the expected long-term repeated use of the nasal spray as a prophylaxis, we used a human antibody to reduce the risk of immunogenicity, which occurs when a foreign substance provokes an immune response.

14. Will a nasal spray substitute for vaccines or face masks?

We envision the InvisiMask nasal spray as a complement to vaccines, therapeutics and other preventive measures such as face masks. A preventive nasal spray adds to the arsenal of tools that can be used to fight the spread of COVID-19. It can be used to provide additional protection in conjunction with face masks or in situations in which face mask wearing is impractical.

15. Can an antibody nasal spray be used to prevent other airborne diseases?

Yes, the concept of a preventative antibody nasal spray can be applied to other airborne pathogens if a neutralizing antibody with high binding affinity and specificity can be identified. The antibody may require additional engineering to increase its retention on the respiratory mucosal surfaces and would need to be tested for use in a nasal spray format.

16. What is Eureka’s experience in developing antibodies?

Eureka has more than 14 years of experience using our antibody expertise to develop drug candidates against both solid and hematological cancers. Eureka is a pioneer in developing TCR-mimic antibodies to target “undruggable” cancer antigens in solid cancers. Our BCMA and GPRC5D antibodies, which we co-developed with the Memorial Sloan Kettering Cancer Center and licensed to Juno Therapeutics (a Bristol-Myers Squibb company), have demonstrated significant response rates in patients with multiple myeloma.

17. How did you invent the InvisiMask nasal spray?

Eureka’s proprietary E-ALPHA antibody human phage library is one of the largest in the world with a diversity of more than 100 billion different antibody candidates. We used our E-ALPHA library to screen for, characterize, and optimize antibodies that can bind to the SARS-CoV-2 spike protein and block the spike protein from binding to the ACE2 receptor. The lead antibody was selected by screening for high binding affinity and selectivity to the SARS-CoV-2 S1 spike protein. The antibody was additionally engineered to increase its retention in the respiratory pathways to extend the duration of protection against infection.

18. Is there a paper describing the InvisiMask nasal spray study?

Yes, results from our study are posted on the preprint server [bioRxiv](https://www.biorxiv.org/).

19. Whom should I contact if I have inquiries about the InvisiMask nasal spray?

For all inquiries, please e-mail: invisimask@eurekainc.com.

20. Where do I learn more about the InvisiMask nasal spray?

To learn more about the InvisiMask nasal spray, visit www.eurekatherapeutics.com/COVID19.

[Continued on Next Page]

21. Can you summarize the key attributes and advantages of the InvisiMask nasal spray?

| Key Attributes | Advantages |
|--|--|
| Nasal spray format | <ul style="list-style-type: none"> • Low cost and ease for personal administration • Provides at least 10 hours of protection in mice exposed to the highest viral load tested • Use as an additional means of protection against infection, for high risk individuals, and in situations in which face mask wearing is impractical • Storage at room temperature with long shelf life in comparison to vaccines (sub-zero storage) will simplify distribution and expand access • Complement to vaccines, therapeutics and other preventive measures such as face masks in slowing spread of COVID-19 |
| Anti-SARS-CoV-2 human IgG antibodies | <ul style="list-style-type: none"> • Anti-SARS-CoV-2 antibody treatments have already been approved by the FDA for confirmed cases of COVID-19 • Antibodies provide active protection in neutralizing the SARS-CoV-2 virus • IgG antibody manufacturing process is well-established and versatile for large scale production • Eureka’s InvisiMask antibodies have been tested against more than 20 SARS-CoV-2 variants reported in COVID-19 patients, including the highly infectious D614G mutant • Human antibody reduces risk of immune response to nasal spray made with foreign peptides or non-human originated antibodies |
| High Affinity and Specificity Antibodies | <ul style="list-style-type: none"> • Provides potent neutralization of SARS-CoV-2 virus at low doses • Low risk of cross-reactivity with non-spike protein targets |
| Proprietary Adhesion Technology | <ul style="list-style-type: none"> • Increases the retention time of the antibody on respiratory mucosal surfaces and extends the duration of protection against infection |
